A Roadmap for the Success of Oncolytic Parvovirus-Based Anticancer Therapies

Literature Cited

1. 1. 

   Kelly E, Russell SJ. 2007. History of oncolytic viruses: genesis to genetic engineering. Mol. Ther. 15:651–59
   [Google Scholar]
2. 2. 

   Kaufman HL, Kohlhapp FJ, Zloza A 2015. Oncolytic viruses: a new class of immunotherapy drugs. Nat. Rev. Drug Discov. 14:642–62
   [Google Scholar]
3. 3. 

   Achard C, Surendran A, Wedge ME, Ungerechts G, Bell J, Ilkow CS 2018. Lighting a fire in the tumor microenvironment using oncolytic immunotherapy. EBioMedicine 31:17–24
   [Google Scholar]
4. 4. 

   Marchini A, Daeffler L, Pozdeev VI, Angelova A, Rommelaere J 2019. Immune conversion of tumor microenvironment by oncolytic viruses: the protoparvovirus H-1PV case study. Front. Immunol. 10:1848
   [Google Scholar]
5. 5. 

   Zamarin D, Holmgaard RB, Subudhi SK, Park JS, Mansour M et al. 2014. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci. Transl. Med. 6:226ra32
   [Google Scholar]
6. 6. 

   Guedan S, Alemany R. 2018. CAR-T cells and oncolytic viruses: joining forces to overcome the solid tumor challenge. Front. Immunol. 9:2460
   [Google Scholar]
7. 7. 

   Chiocca EA, Rabkin SD. 2014. Oncolytic viruses and their application to cancer immunotherapy. Cancer Immunol. Res. 2:295–300
   [Google Scholar]
8. 8. 

   Ottolino-Perry K, Diallo JS, Lichty BD, Bell JC, McCart JA 2010. Intelligent design: combination therapy with oncolytic viruses. Mol. Ther. 18:251–63
   [Google Scholar]
9. 9. 

   Wennier ST, Liu J, McFadden G 2012. Bugs and drugs: oncolytic virotherapy in combination with chemotherapy. Curr. Pharm. Biotechnol. 13:1817–33
   [Google Scholar]
10. 10. 

    Marchini A, Scott EM, Rommelaere J 2016. Overcoming barriers in oncolytic virotherapy with HDAC inhibitors and immune checkpoint blockade. Viruses 8:e9
    [Google Scholar]
11. 11. 

    Fountzilas C, Patel S, Mahalingam D 2017. Review: oncolytic virotherapy, updates and future directions. Oncotarget 8:102617–39
    [Google Scholar]
12. 12. 

    Conry RM, Westbrook B, McKee S, Norwood TG 2018. Talimogene laherparepvec: first in class oncolytic virotherapy. Hum. Vaccin. Immunother. 14:839–46
    [Google Scholar]
13. 13. 

    Lawler SE, Speranza MC, Cho CF, Chiocca EA 2017. Oncolytic viruses in cancer treatment: a review. JAMA Oncol 3:841–49
    [Google Scholar]
14. 14. 

    Eissa IR, Bustos-Villalobos I, Ichinose T, Matsumura S, Naoe Y et al. 2018. The current status and future prospects of oncolytic viruses in clinical trials against melanoma, glioma, pancreatic, and breast cancers. Cancers 10:356
    [Google Scholar]
15. 15. 

    Keller BA, Bell JC. 2016. Oncolytic viruses—immunotherapeutics on the rise. J. Mol. Med. 94:979–91
    [Google Scholar]
16. 16. 

    Lichty BD, Breitbach CJ, Stojdl DF, Bell JC 2014. Going viral with cancer immunotherapy. Nat. Rev. Cancer 14:559–67
    [Google Scholar]
17. 17. 

    LaRocca CJ, Warner SG. 2018. Oncolytic viruses and checkpoint inhibitors: combination therapy in clinical trials. Clin. Transl. Med. 7:35
    [Google Scholar]
18. 18. 

    Durham NM, Mulgrew K, McGlinchey K, Monks NR, Ji H et al. 2017. Oncolytic VSV primes differential responses to immuno-oncology therapy. Mol. Ther. 25:1917–32
    [Google Scholar]
19. 19. 

    Liu Z, Ravindranathan R, Kalinski P, Guo ZS, Bartlett DL 2017. Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy. Nat. Commun. 8:14754
    [Google Scholar]
20. 20. 

    Woller N, Gurlevik E, Fleischmann-Mundt B, Schumacher A, Knocke S et al. 2015. Viral infection of tumors overcomes resistance to PD-1-immunotherapy by broadening neoantigenome-directed T-cell responses. Mol. Ther. 23:1630–40
    [Google Scholar]
21. 21. 

    Samson A, Scott KJ, Taggart D, West EJ, Wilson E et al. 2018. Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade. Sci. Transl. Med. 10:eaam7577
    [Google Scholar]
22. 22. 

    Bourgeois-Daigneault MC, Roy DG, Aitken AS, El Sayes N, Martin NT et al. 2018. Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy. Sci. Transl. Med. 10:eaao1641
    [Google Scholar]
23. 23. 

    Chesney J, Puzanov I, Collichio F, Singh P, Milhem MM et al. 2018. Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma. J. Clin. Oncol. 36:1658–67
    [Google Scholar]
24. 24. 

    Puzanov I, Milhem MM, Minor D, Hamid O, Li A et al. 2016. Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma. J. Clin. Oncol. 34:2619–26
    [Google Scholar]
25. 25. 

    Dummer R, Hoeller C, Gruter IP, Michielin O 2017. Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors. Cancer Immunol. Immunother. 66:683–95
    [Google Scholar]
26. 26. 

    Toolan HW. 1967. Lack of oncogenic effect of the H-viruses for hamsters. Nature 214:10366
    [Google Scholar]
27. 27. 

    Toolan HW, Dalldore G, Barclay M, Chandra S, Moore AE 1960. An unidentified, filtrable agent isolated from transplanted human tumors. PNAS 46:1256–58
    [Google Scholar]
28. 28. 

    Toolan HW, Ledinko N. 1968. Inhibition by H-1 virus of the incidence of tumors produced by adenovirus 12 in hamsters. Virology 35:475–78
    [Google Scholar]
29. 29. 

    Toolan HW, Rhode SL, Gierthy JF 1982. Inhibition of 7,12-dimethylbenz(a)anthracene-induced tumors in Syrian hamsters by prior infection with H-1 parvovirus. Cancer Res 42:2552
    [Google Scholar]
30. 30. 

    Angelova AL, Aprahamian M, Grekova SP, Hajri A, Leuchs B et al. 2009. Improvement of gemcitabine-based therapy of pancreatic carcinoma by means of oncolytic parvovirus H-1PV. Clin. Cancer Res. 15:511–19
    [Google Scholar]
31. 31. 

    Di Piazza M, Mader C, Geletneky K, Herrero YCM, Weber E et al. 2007. Cytosolic activation of cathepsins mediates parvovirus H-1-induced killing of cisplatin and TRAIL-resistant glioma cells. J. Virol. 81:4186–98
    [Google Scholar]
32. 32. 

    Dupressoir T, Vanacker JM, Cornelis JJ, Duponchel N, Rommelaere J 1989. Inhibition by parvovirus H-1 of the formation of tumors in nude mice and colonies in vitro by transformed human mammary epithelial cells. Cancer Res 49:3203–8
    [Google Scholar]
33. 33. 

    Herrero YCM, Cornelis JJ, Herold-Mende C, Rommelaere J, Schlehofer JR, Geletneky K 2004. Parvovirus H-1 infection of human glioma cells leads to complete viral replication and efficient cell killing. Int. J. Cancer 109:76–84
    [Google Scholar]
34. 34. 

    Hristov G, Kramer M, Li J, El-Andaloussi N, Mora R et al. 2010. Through its nonstructural protein NS1, parvovirus H-1 induces apoptosis via accumulation of reactive oxygen species. J. Virol. 84:5909–22
    [Google Scholar]
35. 35. 

    Moehler MH, Zeidler M, Wilsberg V, Cornelis JJ, Woelfel T et al. 2005. Parvovirus H-1-induced tumor cell death enhances human immune response in vitro via increased phagocytosis, maturation, and cross-presentation by dendritic cells. Hum. Gene Ther. 16:996–1005
    [Google Scholar]
36. 36. 

    Geletneky K, Huesing J, Rommelaere J, Schlehofer JR, Leuchs B et al. 2012. Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol. BMC Cancer 12:99
    [Google Scholar]
37. 37. 

    Geletneky K, Kiprianova I, Ayache A, Koch R, Herrero YCM et al. 2010. Regression of advanced rat and human gliomas by local or systemic treatment with oncolytic parvovirus H-1 in rat models. Neuro Oncol 12:804–14
    [Google Scholar]
38. 38. 

    Li J, Bonifati S, Hristov G, Marttila T, Valmary-Degano S et al. 2013. Synergistic combination of valproic acid and oncolytic parvovirus H-1PV as a potential therapy against cervical and pancreatic carcinomas. EMBO Mol. Med. 5:1537–55
    [Google Scholar]
39. 39. 

    Hajda J, Lehmann M, Krebs O, Kieser M, Geletneky K et al. 2017. A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in patients with metastatic, inoperable pancreatic cancer: ParvOryx02 protocol. BMC Cancer 17:576
    [Google Scholar]
40. 40. 

    Geletneky K, Hajda J, Angelova AL, Leuchs B, Capper D et al. 2017. Oncolytic H-1 parvovirus shows safety and signs of immunogenic activity in a first phase I/IIa glioblastoma trial. Mol. Ther. 25:2620–34
    [Google Scholar]
41. 41. 

    Caillet-Fauquet P, Perros M, Brandenburger A, Spegelaere P, Rommelaere J 1990. Programmed killing of human cells by means of an inducible clone of parvoviral genes encoding non-structural proteins. EMBO J 9:2989–95
    [Google Scholar]
42. 42. 

    Cotmore SF, Tattersall P. 2007. Parvoviral host range and cell entry mechanisms. Adv. Virus Res. 70:183–232
    [Google Scholar]
43. 43. 

    Cotmore SF, Agbandje-McKenna M, Chiorini JA, Mukha DV, Pintel DJ et al. 2014. The family Parvoviridae. Arch. . Virol 159:1239–47
    [Google Scholar]
44. 44. 

    Cotmore SF, Agbandje-McKenna M, Canuti M, Chiorini JA, Eis-Hubinger AM et al. 2019. ICTV virus taxonomy profile: Parvoviridae. J. Gen. Virol. 100:367–68
    [Google Scholar]
45. 45. 

    Angelova AL, Geletneky K, Nüesch JP, Rommelaere J 2015. Tumor selectivity of oncolytic parvoviruses: from in vitro and animal models to cancer patients. Front. Bioeng. Biotech. 3:55
    [Google Scholar]
46. 46. 

    Bretscher C, Marchini A. 2019. H-1 parvovirus as a cancer-killing agent: past, present, and future. Viruses 11:e562
    [Google Scholar]
47. 47. 

    Marchini A, Bonifati S, Scott EM, Angelova AL, Rommelaere J 2015. Oncolytic parvoviruses: from basic virology to clinical applications. Virol. J. 12:6
    [Google Scholar]
48. 48. 

    Nüesch JP, Lacroix J, Marchini A, Rommelaere J 2012. Molecular pathways: rodent parvoviruses—mechanisms of oncolysis and prospects for clinical cancer treatment. Clin. Cancer Res. 18:3516–23
    [Google Scholar]
49. 49. 

    Deleu L, Pujol A, Faisst S, Rommelaere J 1999. Activation of promoter P4 of the autonomous parvovirus minute virus of mice at early S phase is required for productive infection. J. Virol. 73:3877–85
    [Google Scholar]
50. 50. 

    Bashir T, Horlein R, Rommelaere J, Willwand K 2000. Cyclin A activates the DNA polymerase δ-dependent elongation machinery in vitro: a parvovirus DNA replication model. PNAS 97:5522–27
    [Google Scholar]
51. 51. 

    Bar S, Rommelaere J, Nüesch JP 2015. PKCη/Rdx-driven phosphorylation of PDK1: a novel mechanism promoting cancer cell survival and permissiveness for parvovirus-induced lysis. PLOS Pathog 11:e1004703
    [Google Scholar]
52. 52. 

    Lachmann S, Bar S, Rommelaere J, Nüesch JP 2008. Parvovirus interference with intracellular signalling: mechanism of PKCη activation in MVM-infected A9 fibroblasts. Cell Microbiol 10:755–69
    [Google Scholar]
53. 53. 

    Salome N, van Hille B, Geuskens M, Rommelaere J 1989. Partial reversion of conditional transformation correlates with a decrease in the sensitivity of rat cells to killing by the parvovirus minute virus of mice but not in their capacity for virus production: effect of a temperature-sensitive v-src oncogene. J. Virol. 63:4797–807
    [Google Scholar]
54. 54. 

    Mousset S, Cornelis J, Spruyt N, Rommelaere J 1986. Transformation of established murine fibro-blasts with an activated cellular Harvey-ras oncogene or the polyoma virus middle T gene increases cell permissiveness to parvovirus minute-virus-of-mice. Biochemie 68:951–55
    [Google Scholar]
55. 55. 

    Gujar S, Pol JG, Kim Y, Lee PW, Kroemer G 2018. Antitumor benefits of antiviral immunity: an underappreciated aspect of oncolytic virotherapies. Trends Immunol 39:209–21
    [Google Scholar]
56. 56. 

    Paglino JC, Andres W, van den Pol AN 2014. Autonomous parvoviruses neither stimulate nor are inhibited by the type I interferon response in human normal or cancer cells. J. Virol. 88:4932–42
    [Google Scholar]
57. 57. 

    Angelova A, Rommelaere J. 2019. Immune system stimulation by oncolytic rodent protoparvoviruses. Viruses 11:e415
    [Google Scholar]
58. 58. 

    Grekova S, Zawatzky R, Horlein R, Cziepluch C, Mincberg M et al. 2010. Activation of an antiviral response in normal but not transformed mouse cells: a new determinant of minute virus of mice oncotropism. J. Virol. 84:516–31
    [Google Scholar]
59. 59. 

    Allaume X, El-Andaloussi N, Leuchs B, Bonifati S, Kulkarni A et al. 2012. Retargeting of rat parvovirus H-1PV to cancer cells through genetic engineering of the viral capsid. J. Virol. 86:3452–65
    [Google Scholar]
60. 60. 

    Ros C, Bayat N, Wolfisberg R, Almendral JM 2017. Protoparvovirus cell entry. Viruses 9:313
    [Google Scholar]
61. 61. 

    Lopez-Bueno A, Rubio MP, Bryant N, McKenna R, Agbandje-McKenna M, Almendral JM 2006. Host-selected amino acid changes at the sialic acid binding pocket of the parvovirus capsid modulate cell binding affinity and determine virulence. J. Virol. 80:1563–73
    [Google Scholar]
62. 62. 

    Balakrishnan B, Jayandharan GR. 2014. Basic biology of adeno-associated virus (AAV) vectors used in gene therapy. Curr. Gene Ther. 14:86–100
    [Google Scholar]
63. 63. 

    Pillay S, Carette JE. 2017. Host determinants of adeno-associated viral vector entry. Curr. Opin. Virol. 24:124–31
    [Google Scholar]
64. 64. 

    Chen AY, Qiu J. 2010. Parvovirus infection-induced cell death and cell cycle arrest. Future Virol 5:731–43
    [Google Scholar]
65. 65. 

    Op De Beeck A, Caillet-Fauquet P 1997. The NS1 protein of the autonomous parvovirus minute virus of mice blocks cellular DNA replication: a consequence of lesions to the chromatin. ? J. Virol. 71:5323–29
    [Google Scholar]
66. 66. 

    Adeyemi RO, Landry S, Davis ME, Weitzman MD, Pintel DJ 2010. Parvovirus minute virus of mice induces a DNA damage response that facilitates viral replication. PLOS Pathog 6:e1001141
    [Google Scholar]
67. 67. 

    Majumder K, Etingov I, Pintel DJ 2017. Protoparvovirus interactions with the cellular DNA damage response. Viruses 9:e323
    [Google Scholar]
68. 68. 

    Nüesch JP, Lachmann S, Rommelaere J 2005. Selective alterations of the host cell architecture upon infection with parvovirus minute virus of mice. Virology 331:159–74
    [Google Scholar]
69. 69. 

    Nykky J, Vuento M, Gilbert L 2014. Role of mitochondria in parvovirus pathology. PLOS ONE 9:e86124
    [Google Scholar]
70. 70. 

    Meszaros I, Toth R, Olasz F, Tijssen P, Zadori Z 2017. The SAT protein of porcine parvovirus accelerates viral spreading through induction of irreversible endoplasmic reticulum stress. J. Virol. 91:e00627-17
    [Google Scholar]
71. 71. 

    Porwal M, Cohen S, Snoussi K, Popa-Wagner R, Anderson F et al. 2013. Parvoviruses cause nuclear envelope breakdown by activating key enzymes of mitosis. PLOS Pathog 9:e1003671
    [Google Scholar]
72. 72. 

    Ohshima T, Iwama M, Ueno Y, Sugiyama F, Nakajima T et al. 1998. Induction of apoptosis in vitro and in vivo by H-1 parvovirus infection. J. Gen. Virol. 79:part 123067–71
    [Google Scholar]
73. 73. 

    Ran Z, Rayet B, Rommelaere J, Faisst S 1999. Parvovirus H-1-induced cell death: influence of intracellular NAD consumption on the regulation of necrosis and apoptosis. Virus Res 65:161–74
    [Google Scholar]
74. 74. 

    Scherz-Shouval R, Elazar Z. 2007. ROS, mitochondria and the regulation of autophagy. Trends Cell Biol 17:422–27
    [Google Scholar]
75. 75. 

    Angelova AL, Grekova SP, Heller A, Kuhlmann O, Soyka E et al. 2014. Complementary induction of immunogenic cell death by oncolytic parvovirus H-1PV and gemcitabine in pancreatic cancer. J. Virol. 88:5263–76
    [Google Scholar]
76. 76. 

    Moehler M, Zeidler M, Schede J, Rommelaere J, Galle PR et al. 2003. Oncolytic parvovirus H1 induces release of heat-shock protein HSP72 in susceptible human tumor cells but may not affect primary immune cells. Cancer Gene Ther 10:477–80
    [Google Scholar]
77. 77. 

    Grekova SP, Raykov Z, Zawatzky R, Rommelaere J, Koch U 2012. Activation of a glioma-specific immune response by oncolytic parvovirus minute virus of mice infection. Cancer Gene Ther 19:468–75
    [Google Scholar]
78. 78. 

    Bhat R, Rommelaere J. 2013. NK-cell-dependent killing of colon carcinoma cells is mediated by natural cytotoxicity receptors (NCRs) and stimulated by parvovirus infection of target cells. BMC Cancer 13:367
    [Google Scholar]
79. 79. 

    Bhat R, Dempe S, Dinsart C, Rommelaere J 2011. Enhancement of NK cell antitumor responses using an oncolytic parvovirus. Int. J. Cancer 128:908–19
    [Google Scholar]
80. 80. 

    Geletneky K, Nüesch JP, Angelova A, Kiprianova I, Rommelaere J 2015. Double-faceted mechanism of parvoviral oncosuppression. Curr. Opin. Virol. 13:17–24
    [Google Scholar]
81. 81. 

    Raykov Z, Grekova S, Galabov AS, Balboni G, Koch U et al. 2007. Combined oncolytic and vaccination activities of parvovirus H-1 in a metastatic tumor model. Oncol. Rep. 17:1493–99
    [Google Scholar]
82. 82. 

    Callaway HM, Feng KH, Lee DW, Allison AB, Pinard M et al. 2017. Parvovirus capsid structures required for infection: mutations controlling receptor recognition and protease cleavages. J. Virol. 91:e01871-16
    [Google Scholar]
83. 83. 

    Mietzsch M, Penzes JJ, Agbandje-McKenna M 2019. Twenty-five years of structural parvovirology. Viruses 11:e362
    [Google Scholar]
84. 84. 

    Grueso E, Sanchez-Martinez C, Calvo-Lopez T, de Miguel FJ, Blanco-Menendez N et al. 2019. Antiangiogenic vascular endothelial growth factor-blocking peptides displayed on the capsid of an infectious oncolytic parvovirus: assembly and immune interactions. J. Virol. 93:e00798-19
    [Google Scholar]
85. 85. 

    Grimm D, Buning H. 2017. Small but increasingly mighty: latest advances in AAV vector research, design, and evolution. Hum. Gene Ther. 28:1075–86
    [Google Scholar]
86. 86. 

    Paglino J, Tattersall P. 2011. The parvoviral capsid controls an intracellular phase of infection essential for efficient killing of stepwise-transformed human fibroblasts. Virology 416:32–41
    [Google Scholar]
87. 87. 

    Marr M, D'Abramo A, Pittman N, Agbandje-McKenna M, Cotmore SF, Tattersall P 2018. Optimizing the targeting of mouse parvovirus 1 to murine melanoma selects for recombinant genomes and novel mutations in the viral capsid gene. Viruses 10:e54
    [Google Scholar]
88. 88. 

    Etingov I, Itah R, Mincberg M, Keren-Naus A, Nam HJ et al. 2008. An extension of the Minute Virus of Mice tissue tropism. Virology 379:245–55
    [Google Scholar]
89. 89. 

    Weinmann J, Grimm D. 2017. Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53:707–13
    [Google Scholar]
90. 90. 

    El-Andaloussi N, Bonifati S, Kaufmann JK, Mailly L, Daeffler L et al. 2012. Generation of an adenovirus-parvovirus chimera with enhanced oncolytic potential. J. Virol. 86:10418–31
    [Google Scholar]
91. 91. 

    Hagedorn C, Kreppel F. 2017. Capsid engineering of adenovirus vectors: overcoming early vector-host interactions for therapy. Hum. Gene Ther. 28:820–32
    [Google Scholar]
92. 92. 

    Lopez-Bueno A, Mateu MG, Almendral JM 2003. High mutant frequency in populations of a DNA virus allows evasion from antibody therapy in an immunodeficient host. J. Virol. 77:2701–8
    [Google Scholar]
93. 93. 

    Allison AB, Kohler DJ, Ortega A, Hoover EA, Grove DM et al. 2014. Host-specific parvovirus evolution in nature is recapitulated by in vitro adaptation to different carnivore species. PLOS Pathog 10:e1004475
    [Google Scholar]
94. 94. 

    Faisst S, Faisst SR, Dupressoir T, Plaza S, Pujol A et al. 1995. Isolation of a fully infectious variant of parvovirus H-1 supplanting the standard strain in human cells. J. Virol. 69:4538–43
    [Google Scholar]
95. 95. 

    Hashemi H, Condurat AL, Stroh-Dege A, Weiss N, Geiss C et al. 2018. Mutations in the non-structural protein-coding sequence of protoparvovirus H-1PV enhance the fitness of the virus and show key benefits regarding the transduction efficiency of derived vectors. Viruses 10:e150
    [Google Scholar]
96. 96. 

    Weiss N, Stroh-Dege A, Rommelaere J, Dinsart C, Salome N 2012. An in-frame deletion in the NS protein-coding sequence of parvovirus H-1PV efficiently stimulates export and infectivity of progeny virions. J. Virol. 86:7554–64
    [Google Scholar]
97. 97. 

    Nüesch J, Thomas N, Plotzky C, Jean R 2013. Modified rodent parvovirus capable of propagating and spreading through human gliomas European Patent EP 2 384 761 A1
98. 98. 

    Daeffler L, Horlein R, Rommelaere J, Nüesch JP 2003. Modulation of minute virus of mice cytotoxic activities through site-directed mutagenesis within the NS coding region. J. Virol. 77:12466–78
    [Google Scholar]
99. 99. 

    El-Andaloussi N, Endele M, Leuchs B, Bonifati S, Kleinschmidt J et al. 2011. Novel adenovirus-based helper system to support production of recombinant parvovirus. Cancer Gene Ther 18:240–49
    [Google Scholar]
100. 100. 

     Raykov Z, Grekova S, Leuchs B, Aprahamian M, Rommelaere J 2008. Arming parvoviruses with CpG motifs to improve their oncosuppressive capacity. Int. J. Cancer 122:2880–84
     [Google Scholar]
101. 101. 

     Grekova SP, Aprahamian M, Giese NA, Bour G, Giese T et al. 2014. Genomic CpG enrichment of oncolytic parvoviruses as a potent anticancer vaccination strategy for the treatment of pancreatic adenocarcinoma. J. Vaccines Vaccin. 5:e1000227
     [Google Scholar]
102. 102. 

     Illarionova A, Rommelaere J, Leuchs B, Marchini A 2012. Modified parvovirus useful for gene silencing European Patent EP2620503
103. 103. 

     El-Andaloussi N, Leuchs B, Bonifati S, Rommelaere J, Marchini A 2012. Efficient recombinant parvovirus production with the help of adenovirus-derived systems. J. Vis. Exp. 62:e3518
     [Google Scholar]
104. 104. 

     Xu P, Wang X, Li Y, Qiu J 2019. Establishment of a parvovirus B19 NS1-expressing recombinant adenoviral vector for killing megakaryocytic leukemia cells. Viruses 11:e820
     [Google Scholar]
105. 105. 

     Kruger L, Eskerski H, Dinsart C, Cornelis J, Rommelaere J et al. 2008. Augmented transgene expression in transformed cells using a parvoviral hybrid vector. Cancer Gene Ther 15:252–67
     [Google Scholar]
106. 106. 

     Jimenez-Chavez AJ, Moreno-Fierros L, Bustos-Jaimes I 2019. Therapy with multi-epitope virus-like particles of B19 parvovirus reduce tumor growth and lung metastasis in an aggressive breast cancer mouse model. Vaccine 37:7256–68
     [Google Scholar]
107. 107. 

     Moehler M, Sieben M, Roth S, Springsguth F, Leuchs B et al. 2011. Activation of the human immune system by chemotherapeutic or targeted agents combined with the oncolytic parvovirus H-1. BMC Cancer 11:464
     [Google Scholar]
108. 108. 

     Moehler M, Blechacz B, Weiskopf N, Zeidler M, Stremmel W et al. 2001. Effective infection, apoptotic cell killing and gene transfer of human hepatoma cells but not primary hepatocytes by parvovirus H1 and derived vectors. Cancer Gene Ther 8:158–67
     [Google Scholar]
109. 109. 

     Muharram G, Le Rhun E, Loison I, Wizla P, Richard A et al. 2010. Parvovirus H-1 induces cytopathic effects in breast carcinoma-derived cultures. Breast Cancer Res. Treat. 121:23–33
     [Google Scholar]
110. 110. 

     Lacroix J, Kis Z, Josupeit R, Schlund F, Stroh-Dege A et al. 2018. Preclinical testing of an oncolytic parvovirus in Ewing sarcoma: Protoparvovirus H-1 induces apoptosis and lytic infection in vitro but fails to improve survival in vivo. Viruses 10:e302
     [Google Scholar]
111. 111. 

     Liu J, Ran ZH, Xiao SD, Rommelaere J 2005. Changes in gene expression profiles induced by parvovirus H-1 in human gastric cancer cells. Chin. J. Dig. Dis. 6:72–81
     [Google Scholar]
112. 112. 

     Lacroix J, Leuchs B, Li J, Hristov G, Deubzer HE et al. 2010. Parvovirus H1 selectively induces cytotoxic effects on human neuroblastoma cells. Int. J. Cancer 127:1230–39
     [Google Scholar]
113. 113. 

     Faisst S, Guittard D, Benner A, Cesbron JY, Schlehofer JR et al. 1998. Dose-dependent regression of HeLa cell-derived tumours in SCID mice after parvovirus H-1 infection. Int. J. Cancer 75:584–89
     [Google Scholar]
114. 114. 

     Angelova AL, Witzens-Harig M, Galabov AS, Rommelaere J 2017. The oncolytic virotherapy era in cancer management: prospects of applying H-1 parvovirus to treat blood and solid cancers. Front. Oncol. 7:93
     [Google Scholar]
115. 115. 

     Angelova AL, Aprahamian M, Balboni G, Delecluse HJ, Feederle R et al. 2009. Oncolytic rat parvovirus H-1PV, a candidate for the treatment of human lymphoma: in vitro and in vivo studies. Mol. Ther. 17:1164–72
     [Google Scholar]
116. 116. 

     Van Pachterbeke C, Tuynder M, Brandenburger A, Leclercq G, Borras M, Rommelaere J 1997. Varying sensitivity of human mammary carcinoma cells to the toxic effect of parvovirus H-1. Eur. J. Cancer 33:1648–53
     [Google Scholar]
117. 117. 

     Van Pachterbeke C, Tuynder M, Cosyn JP, Lespagnard L, Larsimont D, Rommelaere J 1993. Parvovirus H-1 inhibits growth of short-term tumor-derived but not normal mammary tissue cultures. Int. J. Cancer 55:672–77
     [Google Scholar]
118. 118. 

     Wang YY, Liu J, Zheng Q, Ran ZH, Salome N et al. 2012. Effect of the parvovirus H-1 non-structural protein NS1 on the tumorigenicity of human gastric cancer cells. J. Dig. Dis. 13:366–73
     [Google Scholar]
119. 119. 

     Geiss C, Kis Z, Leuchs B, Frank-Stohr M, Schlehofer JR et al. 2017. Preclinical testing of an oncolytic parvovirus: standard protoparvovirus H-1PV efficiently induces osteosarcoma cell lysis in vitro. Viruses 9:e301
     [Google Scholar]
120. 120. 

     Lacroix J, Schlund F, Leuchs B, Adolph K, Sturm D et al. 2014. Oncolytic effects of parvovirus H-1 in medulloblastoma are associated with repression of master regulators of early neurogenesis. Int. J. Cancer 134:703–16
     [Google Scholar]
121. 121. 

     Malerba M, Daeffler L, Rommelaere J, Iggo RD 2003. Replicating parvoviruses that target colon cancer cells. J. Virol. 77:6683–91
     [Google Scholar]
122. 122. 

     Goepfert K, Dinsart C, Rommelaere J, Foerster F, Moehler M 2019. Rational combination of parvovirus H1 with CTLA-4 and PD-1 checkpoint inhibitors dampens the tumor induced immune silencing. Front. Oncol. 9:425
     [Google Scholar]
123. 123. 

     Geletneky K, Bartsch A, Weiss C, Bernhard H, Marchini A, Rommelaere J 2018. ATIM-40. High rate of objective anti-tumor response in 9 patients with glioblastoma after viro-immunotherapy with oncolytic parvovirus H-1 in combination with Bevacicumab and PD-1 checkpoint blockade. Neuro Oncol 20:vi10
     [Google Scholar]
124. 124. 

     Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI et al. 2017. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell 170:1109–19
     [Google Scholar]
125. 125. 

     Geletneky K, Hartkopf AD, Krempien R, Rommelaere J, Schlehofer JR 2010. Therapeutic implications of the enhanced short and long-term cytotoxicity of radiation treatment followed by oncolytic parvovirus H-1 infection in high-grade glioma cells. Bioeng. Bugs 1:429–33
     [Google Scholar]
126. 126. 

     Marchini A, Li J, Schroeder L, Rommelaere J, Geletneky K 2015. Cancer therapy with a parvovirus combined with a Bcl-2 inhibitor European Patent EP 2 829 284 A1
127. 127. 

     Grekova SP, Aprahamian M, Daeffler L, Leuchs B, Angelova A et al. 2011. Interferon γ improves the vaccination potential of oncolytic parvovirus H-1PV for the treatment of peritoneal carcinomatosis in pancreatic cancer. Cancer Biol. Ther. 12:888–95
     [Google Scholar]
128. 128. 

     Johnson DR, O'Neill BP. 2012. Glioblastoma survival in the United States before and during the temozolomide era. J. Neurooncol. 107:359–64
     [Google Scholar]
129. 129. 

     Geletneky K, Hartkopf AD, Krempien R, Rommelaere J, Schlehofer JR 2010. Improved killing of human high-grade glioma cells by combining ionizing radiation with oncolytic parvovirus H-1 infection. J. Biomed. Biotechnol. 2010 350748
     [Google Scholar]
130. 130. 

     Paglino JC, Ozduman K, van den Pol AN 2012. LuIII parvovirus selectively and efficiently targets, replicates in, and kills human glioma cells. J. Virol. 86:7280–91
     [Google Scholar]
131. 131. 

     Abschuetz A, Kehl T, Geibig R, Leuchs B, Rommelaere J, Regnier-Vigouroux A 2006. Oncolytic murine autonomous parvovirus, a candidate vector for glioma gene therapy, is innocuous to normal and immunocompetent mouse glial cells. Cell Tissue Res 325:423–36
     [Google Scholar]
132. 132. 

     Kiprianova I, Thomas N, Ayache A, Fischer M, Leuchs B et al. 2011. Regression of glioma in rat models by intranasal application of parvovirus H-1. Clin. Cancer Res. 17:5333–42
     [Google Scholar]
133. 133. 

     Erdo F, Bors LA, Farkas D, Bajza A, Gizurarson S 2018. Evaluation of intranasal delivery route of drug administration for brain targeting. Brain Res. Bull. 143:155–70
     [Google Scholar]
134. 134. 

     Teague A, Lim KH, Wang-Gillam A 2015. Advanced pancreatic adenocarcinoma: a review of current treatment strategies and developing therapies. Ther. Adv. Med. Oncol. 7:68–84
     [Google Scholar]
135. 135. 

     Grekova S, Aprahamian M, Giese N, Schmitt S, Giese T et al. 2010. Immune cells participate in the oncosuppressive activity of parvovirus H-1PV and are activated as a result of their abortive infection with this agent. Cancer Biol. Ther. 10:1280–89
     [Google Scholar]
136. 136. 

     Mestas J, Hughes CC. 2004. Of mice and not men: differences between mouse and human immunology. J. Immunol. 172:2731–38
     [Google Scholar]
137. 137. 

     Jackson SJ, Thomas GJ. 2017. Human tissue models in cancer research: looking beyond the mouse. Dis. Model. Mech. 10:939–42
     [Google Scholar]
138. 138. 

     Kloker LD, Yurttas C, Lauer UM 2018. Three-dimensional tumor cell cultures employed in virotherapy research. Oncolytic Virother 7:79–93
     [Google Scholar]
139. 139. 

     Josupeit R, Bender S, Kern S, Leuchs B, Hielscher T et al. 2016. Pediatric and adult high-grade glioma stem cell culture models are permissive to lytic infection with parvovirus H-1. Viruses 8:e138
     [Google Scholar]
140. 140. 

     Choi Y, Lee S, Kim K, Kim SH, Chung YJ, Lee C 2018. Studying cancer immunotherapy using patient-derived xenografts (PDXs) in humanized mice. Exp. Mol. Med. 50:99
     [Google Scholar]
141. 141. 

     Zheng B, Ren T, Huang Y, Sun K, Wang S et al. 2018. PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse. J. Hematol. Oncol. 11:16
     [Google Scholar]
142. 142. 

     Freedman JD, Hagel J, Scott EM, Psallidas I, Gupta A et al. 2017. Oncolytic adenovirus expressing bispecific antibody targets T-cell cytotoxicity in cancer biopsies. EMBO Mol. Med. 9:1067–87
     [Google Scholar]
143. 143. 

     Scott EM, Frost S, Khalique H, Freedman JD, Seymour LW, Lei-Rossmann J 2020. Use of liquid patient ascites fluids as a preclinical model for oncolytic virus activity. Oncolytic Viruses CE Engeland 261–70 New York: Springer
     [Google Scholar]
144. 144. 

     Geletneky K, Leoni AL, Pohlmeyer-Esch G, Loebhard S, Leuchs B et al. 2015. Bioavailability, biodistribution, and CNS toxicity of clinical-grade parvovirus H1 after intravenous and intracerebral injection in rats. Comp. Med. 65:36–45
     [Google Scholar]
145. 145. 

     Foreman PM, Friedman GK, Cassady KA, Markert JM 2017. Oncolytic virotherapy for the treatment of malignant glioma. Neurotherapeutics 14:333–44
     [Google Scholar]